Ares Financial Consulting’s Protagonist Therapeutics PTGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-6
Closed -$735 – 1121
2026
Q2
$735 Buy
+6
New +$627 ﹤0.01% 1045

Other funds holding PTGX

Ares Financial Consulting's PTGX Position: Q3 2026 in Review

Ares Financial Consulting sold out of Protagonist Therapeutics (PTGX) in Q3 2026, closing a stake of 6 shares — an estimated $735 sold.

Ares Financial Consulting first reported a position in PTGX in Q2 2026 and held it in 1 quarter. The position peaked at $735 in Q2 2026. 376 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

  • Ares Financial Consulting reported no remaining Protagonist Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Ares Financial Consulting sold 6 Protagonist Therapeutics shares in Q3 2026, an estimated $735.
  • Ares Financial Consulting first reported a position in Protagonist Therapeutics in Q2 2026 and held it in 1 quarter.
  • Ares Financial Consulting's Protagonist Therapeutics position peaked at $735 in Q2 2026.
  • 376 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.